Décisions officielles de classement tarifaire publiées par la Commission européenne
5 Règlements
A product put up for retail sale in gelatine capsules, one capsule consisting of (mg): — simethicone: 257,5 —gelatine, glycerol, dimethicone, titanium dioxide (E 171), potassium sorbate, food colourants E 110 and E 122: approx. 196 The product soothes stomach pain and prevents bloating and flatulence. According to its label, the product is presented for human consumption with a recommended daily dose of one to two capsules after each main meal of the day.
Classification is determined by the general rules 1 and 6 for the interpretation of the Combined Nomenclature, Note 1(f) to Chapter 21 and the wording of CN codes 3004 and 3004 90 00 . The product, due to the presence of simethicone, has therapeutic properties. Its classification under heading 2106 as a food preparation not elsewhere specified or included is therefore excluded (see Note 1(f) to Chapter 21). The product is put up for retail sale in measured doses and exhibits clearly defined prophylactic or therapeutic properties, e.g. against functional dyspepsia. The product is therefore to be classified as a medicament put up in measured doses for retail sale in CN code 3004 90 00. Documented CN 2026 code: 30049000. Commission 2026 transposition note: “Note 1(f) to Chapter 21” to be replaced by Note 1(g) to Chapter 21”
8 juin 2016
The product is put up for retail sale in tablet form with a total weight of ca. 900 mg each, one tablet consisting of (mg): — alpha-lipoic acid 300, — calcium (as dibasic calcium phosphate) 88,5, — microcrystalline cellulose, hydroxypropyl ethylcellulose, colloidal silicon dioxide and magnesium stearate ca. 511. According to the label, the product is presented as a food supplement for human consumption. The recommended daily dose indicated on the label is one tablet per day.
Classification is determined by the General Rules 1 and 6 for the interpretation of the Combined Nomenclature and the wording of CN codes 3004 and 3004 90 00. Although the product is presented as a food supplement, it has effects in the field of the prevention or treatment of diseases or ailments. Its classification under heading 2106 as a food preparation not elsewhere specified or included is therefore excluded (see also Harmonized System Explanatory Notes to heading 2106, point (16)). The product is put up for retail sale in measured doses and exhibits clearly defined prophylactic or therapeutic properties, e.g. against polyneuropathy. It is therefore to be classified as a medicament put up in measured doses for retail sale of heading 3004. Documented CN 2026 code: 30049000.
28 nov. 2013
Eyecare product (ophthalmic solution) composed of the active ingredient: poly(vinyl alcohol) (lubricant) 1,4 %, and of the other ingredients: sodium chloride (tonicity agent); sodium dihydrogenphosphate (buffering agent); disodium hydrogenphosphate (buffering agent); benzalkonium chloride (preservative); disodium edetate (chelating agent); hydrochloric acid (pH- adjuster); sodium hydroxide (pH- adjuster); and purified water, q.s. to 100 % (vehicle). The product is put up for retail sale (15ml-dr
Classification is determined by the provisions of General Rules 1 and 6 for the interpretation of the Combined Nomenclature and by the wording of CN codes 3004 and 3004 90 00. The product is prepared and put up for therapeutic use as a lubricant and artificial tear in dry-eye and other ocular irritation syndromes. The preparation is not for use as a contact lens or artificial eye solution of heading 3307. Documented CN 2026 code: 30049000.
28 juil. 2004
Item 1: Amber syrup, intended to correct iron- deficiency, put up in 125-ml bottles. Its composition per 100 g is: 4,13 g sodium feredetate (a soluble ferric compound of crystallised sodium ethylenediamine tetra-acetate), 24 g sorbitol, 13 g glycerine, 0,1 g citric acid, 0,09 g ethyl alcohol 95°, 0,01 g flavouring agent, 0,01 g propyl parahydroxybenzoate, 0,08 g methyl parahydroxybenzoate, and quant.suff. water.
Classification is determined by the provisions of general rules 1 and 6 for the interpretation of the Combined Nomenclature and by the wording of CN codes 3004 and 3004 90 00. This product must be considered as a medicament because of its composition and its use for therapeutic purposes. Documented CN 2026 code: 30049000.
4 déc. 1995
Item 6: Injectable preparation, sterile, pyrogen- free, consisting of purified collagen dispersed in a phosphate-buffered physiological saline solution, whether or not containing lidocaine (INN), put up for retail sale
Classficiation is determined by the provisions of general rules 1 and 6 for the interpretation of the combined nomenclature and the texts of CN codes 3004 and 3004 90 00. This product is used in the treatment of atrophy due to disease, trauma or other disorders of the conjunctive tissue Whereas, in order to ensure uniform Documented CN 2026 code: 30049000.
7 juil. 1989